New Amgen Survey Shows Heart Attack Survivors in Canada Do Not Know Their Cholesterol Level or What It Should Be MISSISSAUGA, ON , Feb. 6, 2020 /CNW/ - In recognition of February as Heart Month, Amgen Canada ("Amgen") today released Canadian findings as part of a global survey1 that evaluated worldwide heart attack survivors' perceptions and awareness of the connection between cholesterol and cardiovascular (CV) events revealing that 56 per cent of respondents in Canada do not consider high cholesterol to be a chronic condition requiring long-term management and care.2 Amgen (CNW Group/Amgen Canada) Low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, is one of the most important modifiable risk factors for heart attack.3 Globally more than 40% of patients who have had a CV event, like a heart attack, will go on to have another within two years.4 The survey's findings show that while heart attack survivors are proactively trying to improve their cardiovascular health, they may not fully understand the importance of lowering high LDL-C to reduce their risk of another heart attack: "Cardiovascular disease remains one of the most significant health challenges in Canada where an estimated 63,200 adults will experience a first heart attack this year7," said Ponda Motsepe-Ditshego, Executive Medical Director at Amgen Canada."This survey shows patients want to reduce their risk of another heart attack, but are unsure about the best actions to take. Continue reading →

The optimal dose of beta blockers after acutemyocardial infarction(MI) remains uncertain. We evaluated the effectiveness of low-dose nebivolol, a beta1 blocker and a vasodilator, in patients with acute MI. A total of 625 patients with acute MI from 14 teaching hospitals in Korea were divided into 2 groups according to the dose of nebivolol (nebistol, Elyson Pharmaceutical Co., Ltd., Seoul, Korea): low-dose group (1.25 mg daily, n=219) and usual- to high-dose group (2.5 mg daily, n=406) Continue reading →

A leading research firm, Zion Market Research added a latest industry report on Myocardial Infarction Treatment Market consisting of 110+ pages during the forecast period and Myocardial Infarction Treatment Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Myocardial Infarction Treatment Market. According to the report the Global Myocardial Infarction Treatment Market Set to reach USD 1726.3 Million by end of 2022 The following report contains an interpretation of the marketing plan for Myocardial Infarction Treatment Market. This Myocardial Infarction Treatment Market report offers the clients with a unique opportunity that can drive them to higher levels of success and to great achievement. Continue reading →